Description
NUCLEAR PHARMACY CONFERENCE
Saturday, October 17, 2026
Therapy Protocols and Extravasations
8:00am-9:30am (1.5 CEUs)
Garcia Simon Clark, PharmD, MS, ANP, CCP, BCNP, Kindred Healthcare, Pharmacy Supervisor
Upon completion of this activity, participants will be able to: Review patient specific communication safety counseling points; Optimize therapy through dosage adjustments and side effect monitoring parameters; Review therapy protocols and patient specific factors; Explain extravasation management pertaining to radiopharmaceuticals.
UAN: 0675-0000-26-035-L01-P
Beyond Perfusion: Cardiac Imaging in Amyloidosis and Sarcoidosis
9:30am-11:00am (1.5 CEUs)
Vesper Grantham, MEd, RT(N), CNMT, Chair, Medical Imaging and Radiation Sciences, Program Director, Nuclear Medicine
Upon completion of this activity, participants will be able to: Discuss the indications and appropriate use of nuclear imaging for the diagnosis and management of cardiac amyloidosis and cardiac sarcoidosis; Contrast the imaging techniques for SPECT/CT cardiac amyloidosis and PET/CT cardiac sarcoidosis; Describe and differentiate the clinical presentation for cardiac amyloidosis and cardiac sarcoidosis.
UAN: 0675-0000-26-036-L01-P
Radiochemical Purity, Calculations and Studies
11:15am-12:45pm (1.5 CEUs)
Wendy Galbraith, PharmD, FAPhA, BCNP, Clinical Associate Professor, University of Oklahoma Dept. of Pharmaceutical Sciences, College of Pharmacy, Nuclear Pharmacy & Research Imaging Facility
Upon completion of this activity, participants will be able to: Explain factors that affect radiochemical purity; Describe radionuclide impurity biodistribution; Perform calculations and sight studies with rigor.
UAN: 0675-0000-26-037-L01-P
Workforce Development and Radiopharma – Tackling Problems That Come with Rapid Growth
12:45pm-2:15pm (1.5 CEUs)
Kara Duncan Weatherman, PharmD, BCNP, FAPhA, Clinical Professor and Director of Radiopharmaceutical Programs, Purdue University
Upon completion of this activity, participants will be able to: Define workforce development and the components necessary for providing a competent and effective team of employees; Illustrate the current workforce status across various aspects of radiopharma; Develop a workforce plan for nuclear pharmacy and identify key academic areas of interest.
UAN: 0675-0000-26-042-L04-P
Off Target; Radiopharmaceutical Medical Events and Misadventures
12:45pm-2:15pm (1.5 CEUs)
Nic Mastascusa, PharmD, BCNP, Clinical Associate Professor of Pharmacy Practice, Department of Pharmacy Practice, Radiopharmaceutical Programs, Sidney & Lois Eskenazi Hospital
Upon completion of this activity, participants will be able to: Define reportable medial events under 10 CFR 35 criteria; Identify hot spot failure points in dispensing and administration; Analyze cases from NRC reportable events to determine contributing factors; Apply NRC minimal criteria to determine if an event qualifies as a reportable event.
UAN: 0675-0000-26-038-L05-P
Sunday, October 18, 2026
49 CFR and IATA Compliance: Safe Transportation of Radioactive Materials and Cold-Chain Pharmaceuticals
8:00am-9:30am (1.5 CEUs)
Ken Ali, AAS, EMBA, CAU, Director, EHS & Radiopharma US-CAN, Compliance Specialist, GE Healthcare
Upon completion of this activity, participants will be able to: Apply 49 CFR and IATA regulations to the classification, packaging, and transportation of Class 7 radioactive materials and cold-chain pharmaceuticals; Perform compliant shipment preparation and documentation, including radiation surveys, Transport Index calculations, contamination testing, labeling, and shipping paper completion; Implement safety, securement, and quality standards through package inspections, vehicle securement, incident reporting, and pre-dispatch compliance checks; Recognize and prevent regulatory violations by identifying common audit findings, documentation errors, and transportation compliance risks; Maintain operational readiness and compliance by following standardized procedures, checklists, and quality control practices.
UAN: 0675-0000-26-039-L03-P
Exploring Drug Safety of Radiopharmaceuticals
9:30am-11:00am (1.5 CEUs)
Nanno Schreuder, PharmD, PhD, Nuclear Pharmacist, GE HealthCare Radiopharmacy Zwolle
Upon completion of this activity, participants will be able to: Describe the frequency and nature of adverse reactions associated with radiopharmaceuticals; Discuss approaches to causality assessment of adverse events; Discuss the role of patient-reported adverse events in improving the detection and understanding of radiopharmaceutical adverse reactions; Identify different types of interactions between radiopharmaceuticals and concomitant medications; Review some relevant examples of drug-radiopharmaceutical interactions; Evaluate safety considerations for the use of radiopharmaceuticals in special patient populations.
UAN: 0675-0000-26-040-L01-P
Hidden in Plain Sight: The Radiopharmacist Behind Every Dose, A Deep Dive in Successful Operations & Scaling Imaging in Theranostics Programs
11:15am-12:45pm (1.5 CEUs)
Mahipal (Paul) Rathod, PharmD, RPh., BCNP, Assistant Director, Nuclear Pharmacy, The James/Wexner Medical Center
Upon completion of this activity, participants will be able to: Describe the evolution of the radiopharmaceutical ecosystem from its history and current state to the emerging technologies, therapies and infrastructure shaping its future; Assess the next wave of radionuclide innovation, including emerging isotopes, their clinical potential, production pathways, availability and access; Recognize the critical role of the radiopharmacist behind each dose and opportunities to expand beyond conventional practice areas into clinical integration, innovation, program development, policy, and strategic leadership; Design a successful theranostics ecosystem and its critical stakeholders.
UAN: 0675-0000-26-041-L01-P
Workforce Development and Radiopharma – Tackling Problems That Come with Rapid Growth
12:45pm-2:15pm (1.5 CEUs)
Kara Duncan Weatherman, PharmD, BCNP, FAPhA, Clinical Professor and Director of Radiopharmaceutical Programs, Purdue University
Upon completion of this activity, participants will be able to: Define workforce development and the components necessary for providing a competent and effective team of employees; Illustrate the current workforce status across various aspects of radiopharma; Develop a workforce plan for nuclear pharmacy and identify key academic areas of interest.
UAN: 0675-0000-26-042-L04-P
